---
title: "Sino Biopharm Advances First-in-Class CCR8 Antibody Into Phase III Gastric Cancer Trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285458913.md"
description: "Sino Biopharmaceutical has announced that its subsidiary LaNova Medicines has enrolled the first patient in a Phase III clinical trial for cafelkibart (LM-108), a CCR8 monoclonal antibody, targeting advanced gastric cancer. This trial follows two Breakthrough Therapy Designations in China and aims to position LM-108 as a first-in-class therapy. Early data indicates improved response rates and survival compared to standard treatments. Analysts rate the stock as a Buy with a target price of HK$8.70, reflecting positive market sentiment."
datetime: "2026-05-06T23:54:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285458913.md)
  - [en](https://longbridge.com/en/news/285458913.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285458913.md)
---

# Sino Biopharm Advances First-in-Class CCR8 Antibody Into Phase III Gastric Cancer Trial

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Sino Biopharmaceutical ( (HK:1177) ) has shared an update.

Sino Biopharmaceutical announced that its subsidiary LaNova Medicines has enrolled the first patient in a Phase III registrational clinical trial of cafelkibart (LM-108), a CCR8 monoclonal antibody, as a second-line treatment for CCR8-positive locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma in combination with a PD-1 inhibitor. This is the second pivotal registrational trial for LM-108, which has already received two Breakthrough Therapy Designations in China and is being positioned as a potential global first-in-class CCR8-targeted therapy.

Earlier Phase I/II data showed that LM-108 combined with toripalimab produced notable improvements in response rates, disease control and survival versus current paclitaxel-based standards, particularly in patients with higher CCR8 expression. By selectively eliminating immunosuppressive regulatory T cells in the tumor microenvironment and potentially overcoming resistance to existing immunotherapies, the program could significantly enhance Sino Biopharmaceutical’s standing in oncology and offer a novel treatment paradigm for second-line advanced gastric cancer and other MSI-H/dMMR solid tumors.

The most recent analyst rating on (HK:1177) stock is a Buy with a HK$8.70 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.

**More about Sino Biopharmaceutical**

Sino Biopharmaceutical Limited is a Hong Kong-listed pharmaceutical group focused on the research, development and commercialization of innovative medicines, particularly in oncology. Through wholly owned subsidiary LaNova Medicines, the company advances cutting-edge biologics, including monoclonal antibodies aimed at addressing high-incidence cancers in China and globally.

**Average Trading Volume:** 70,256,802

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$97.92B

For an in-depth examination of 1177 stock, go to TipRanks’ Overview page.

### Related Stocks

- [01177.HK](https://longbridge.com/en/quote/01177.HK.md)

## Related News & Research

- [Sino Biopharm Showcases Promising Obesity Antibody Data and Expands Weight-Loss Pipeline](https://longbridge.com/en/news/286328735.md)
- [GSK and SBP Group team up to advance bepirovirsen launch in China](https://longbridge.com/en/news/286073604.md)
- [Small study shows one-time cell therapy can control HIV infection](https://longbridge.com/en/news/286002405.md)
- [11:46 ETFirst-in-human trial demonstrates promise of implantable cytokine factories for ovarian cancer](https://longbridge.com/en/news/286128397.md)
- [09:15 ETAutoimmunity BioSolutions Expands Seed Funding Round and Deepens Family Office Participation](https://longbridge.com/en/news/286268726.md)